Eisai Files for Approval of New Alzheimer’s Drug in Japan

From Jiji

January 16 2023

TOKYO – Eisai Co said Monday that it has applied for marketing authorization from Japan’s Pharmaceuticals and Medical Devices Agency for a new Alzheimer’s drug jointly developed with U.S. pharmaceutical company Biogen Inc.

Before submitting the application, the Japanese drugmaker utilized the PMDA’s prior assessment consultation system to shorten the review period for the drug, lecanemab. The company aims to obtain marketing authorization by the end of this year.